A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR

被引:25
|
作者
Wang, Chunsheng [1 ]
Zhao, Kewei [1 ,2 ]
Hu, Shanliang [1 ]
Huang, Yong [3 ]
Ma, Li [3 ]
Song, Yipeng [1 ]
Li, Minghuan [2 ]
机构
[1] Qingdao Univ, Coll Med, Affiliated Yantai Yuhuangding Hosp, Dept Radiat Oncol, 20 Yudong Rd, Yantai 264000, Shandong, Peoples R China
[2] Shandong Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China
[3] Shandong Univ, Shandong Canc Hosp & Inst, Dept Nucl Med, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China
关键词
Esophageal squamous cell carcinoma; Predictive model; Treatment response; Concurrent chemoradiotherapy; SUVmean; NLR; METABOLIC TUMOR VOLUME; LYMPHOCYTE RATIO; NEUTROPHIL/LYMPHOCYTE RATIO; HEMATOLOGICAL PARAMETERS; PATHOLOGICAL RESPONSE; PROGNOSTIC VALUE; LUNG-CANCER; FDG UPTAKE; PET/CT; NEUTROPHIL;
D O I
10.1186/s12885-020-07040-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We conducted this study to combine the mean standardized uptake value (SUVmean) and neutrophil to lymphocyte ratio (NLR) to establish a strong predictive model for patients with esophageal squamous cell carcinoma (ESCC) after concurrent chemoradiotherapy (CCRT). Methods We retrospectively analyzed 163 newly diagnosed ESCC patients treated with CCRT. Eighty patients (training set) were randomly selected to generate cut-off SUVmean and NLR values by receiver operating characteristic (ROC) curve analysis and to establish a predictive model by using the independent predictors of treatment outcomes. Then, we evaluated the performance of the prediction model regarding treatment outcomes in the testing set (n = 83) and in all sets. Results A high SUVmean (> 5.81) and high NLR (> 2.42) at diagnosis were associated with unfavorable treatment outcomes in patients with ESCC. The prediction model had a better performance than the simple parameters (p < 0.05). With a cut-off value of 0.77, the prediction model significantly improved the specificity and positive predictive value for treatment response (88.9 and 92.1% in the training set, 95.8 and 97.1% in the testing set, and 92.2 and 91.8% in all sets, respectively). Conclusions The pretreatment SUVmean and NLR were independent predictors of treatment response in ESCC patients treated with CCRT. The predictive model was constructed based on these two parameters and provides a highly accurate tool for predicting patient outcomes.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Pathologic Response and Tumor-Infiltrating Lymphocytes during Chemoradiotherapy: Promising Predictive and Prognostic Markers for Chemoradiotherapy Response and Outcome in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
    Qian, D.
    Wang, Y.
    Pang, Q.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E39 - E40
  • [42] Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
    Jing, Wang
    Yan, Weiwei
    Liu, Yuguo
    Li, Ji
    Yu, Jinming
    Zhu, Hui
    CANCER BIOLOGY & THERAPY, 2019, 20 (08) : 1121 - 1126
  • [43] Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial
    Li, Hui
    Gu, Dayong
    Du, Mingyu
    Zhou, Guoren
    Zhang, Zhi
    Ye, Jinjun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma
    Hao, Daxuan
    Li, Xue
    Yang, Yuanyuan
    Zhang, Yougai
    Wu, Xiaoyuan
    Chen, Yongshun
    He, Chunyu
    Wang, Wen
    Liu, Jinsong
    Wang, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [45] Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma
    Hao, Daxuan
    Li, Xue
    Yang, Yuanyuan
    Zhang, Yougai
    Wu, Xiaoyuan
    Chen, Yongshun
    Wang, Jianhua
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 (02) : 346 - 353
  • [46] Safety of Neoadjuvant Chemoradiotherapy Followed by Surgery for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
    Herbella, Fernando A. M.
    Patti, Marco G.
    JAMA SURGERY, 2021, 156 (05) : 452 - 452
  • [47] Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma
    Habu, Takumi
    Bando, Hideaki
    Kumanishi, Ryosuke
    Ogata, Takatsugu
    Fujisawa, Takeshi
    Kumagai, Shogo
    Fujiwara, Hisashi
    Mishima, Saori
    Kotani, Daisuke
    Nakamura, Masaki
    Hojo, Hidehiro
    Yoda, Yusuke
    Koyama, Shohei
    Nishikawa, Hiroyoshi
    Yano, Tomonori
    Fujita, Takeo
    Kadowaki, Shigenori
    Muro, Kei
    Kinoshita, Takahiro
    Kojima, Takashi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [48] Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    Park, Sehhoon
    Oh, Dongryul
    Choi, Yoon-La
    Chi, Sang Ah
    Kim, Kyunga
    Ahn, Myung-Ju
    Sun, Jong-Mu
    CANCER, 2022, 128 (11) : 2148 - 2158
  • [49] Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    He, Wenwu
    Leng, Xuefeng
    Wang, Kangning
    Mao, Tiaoqin
    Peng, Lin
    Fang, Qiang
    Xiao, Wenguang
    Han, Yongtao
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (06) : 1105 - 1112
  • [50] Salvage Re-Irradiation Versus-Concurrent Chemoradiotherapy For Esophageal Squamous Cell Carcinoma Patients With Locally Relapse After Definitive Chemoradiotherapy
    Wang, J.
    Gao, G. B.
    Liu, Q.
    Wu, F. P.
    Xiao, L. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E626 - E626